Two snakebite antivenoms have potential to reduce Eswatini’s dependency upon a single, increasingly unavailable product: Results of preclinical efficacy testing

Table 4

The resulting in mean lesion size after intradermal injection with one MND dose of venom preincubated with each of the antivenoms.

The dose of SAIMR Polyvalent in μL was first determined, and the test antivenoms at this fixed volume were then tested to compare lesion size.